 |
| Quantity: | |
|---|---|
Sulfobutyl betacyclodextrin sodium is a new type of anionic highly water-soluble cyclodextrin derivative, which can be well encapsulated with drug molecules to form non-covalent complexes, thus improving drug stability, water solubility, safety, reducing nephrotoxicity, moderating drug hemolysis, controlling drug release rate, and masking bad odor. At present, it has been applied to injectable drugs, oral drugs, nasal drugs and eye drugs, and has special affinity and compatibility for nitrogen-containing drugs.
1. Neutral, positive and negative APIs can be effectively combined with sulfobutyl betacyclodextrin sodium, so that compounds with different solubility in API water can be increased by 10 to 25000 times.
2. Sulfobutyl betacyclodextrin sodium has good biocompatibility and can be administered by injection, oral administration, eye, nose, external use and inhalation.
Sulfobutyl ether- β- Cyclodextrin sodium is a new type of pharmaceutical excipient, belonging to a sulfonic derivative of anionic high water-soluble cyclodextrin. It can well form non-covalent complexes with drug molecules, improve the stability, water solubility and safety of the drug, and effectively improve the biological activity of the drug molecules. It has low nephrotoxicity, can ease the drug hemolysis, and control the drug release rate.
with β- Cyclodextrin and 1,4-sulfobutyrolactone are used as raw materials, and the solubility of 1,4-sulfobutyrolactone and sulfobutyl ether are increased by introducing an appropriate amount of organic solvent into the alkaline aqueous solution- β- Synthesis yield of cyclodextrin; Sulfobutyl ether is obtained from the product solution through ultrasonic dialysis, activated carbon decolorization, freeze drying and other operations- β- Ring paste powder products.
Captisol (SBE- β- CD, Sulfobutylether- β- Cyclodextrin) is a new type of chemically modified cyclodextrin with good stability and solubility.
Sulfobutyl betacyclodextrin sodium is a new type of anionic highly water-soluble cyclodextrin derivative, which can be well encapsulated with drug molecules to form non-covalent complexes, thus improving drug stability, water solubility, safety, reducing nephrotoxicity, moderating drug hemolysis, controlling drug release rate, and masking bad odor. At present, it has been applied to injectable drugs, oral drugs, nasal drugs and eye drugs, and has special affinity and compatibility for nitrogen-containing drugs.
1. Neutral, positive and negative APIs can be effectively combined with sulfobutyl betacyclodextrin sodium, so that compounds with different solubility in API water can be increased by 10 to 25000 times.
2. Sulfobutyl betacyclodextrin sodium has good biocompatibility and can be administered by injection, oral administration, eye, nose, external use and inhalation.
Sulfobutyl ether- β- Cyclodextrin sodium is a new type of pharmaceutical excipient, belonging to a sulfonic derivative of anionic high water-soluble cyclodextrin. It can well form non-covalent complexes with drug molecules, improve the stability, water solubility and safety of the drug, and effectively improve the biological activity of the drug molecules. It has low nephrotoxicity, can ease the drug hemolysis, and control the drug release rate.
with β- Cyclodextrin and 1,4-sulfobutyrolactone are used as raw materials, and the solubility of 1,4-sulfobutyrolactone and sulfobutyl ether are increased by introducing an appropriate amount of organic solvent into the alkaline aqueous solution- β- Synthesis yield of cyclodextrin; Sulfobutyl ether is obtained from the product solution through ultrasonic dialysis, activated carbon decolorization, freeze drying and other operations- β- Ring paste powder products.
Captisol (SBE- β- CD, Sulfobutylether- β- Cyclodextrin) is a new type of chemically modified cyclodextrin with good stability and solubility.
